LC
SUPN icon

Lindbrook Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Lindbrook Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$3.6K Buy
110
+19
+21% +$673 ﹤0.01% 2086
2024
Q4 		$3.29K Buy
91
+8
+10% +$282 ﹤0.01% 2142
2024
Q3 		$2.59K Buy
83
+17
+26% +$531 ﹤0.01% 2266
2024
Q2 		$1.77K Buy
66
+17
+35% +$493 ﹤0.01% 2372
2024
Q1 		$1.67K Hold
49
– – ﹤0.01% 2303
2023
Q4 		$1.42K Buy
49
+35
+250% +$928 ﹤0.01% 2379
2023
Q3 		$386 Buy
+14
New +$426 ﹤0.01% 2574

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Lindbrook Capital's SUPN Position: Q1 2025 in Review

Lindbrook Capital increased its Supernus Pharmaceuticals (SUPN) stake by 21% in Q1 2025, buying an estimated $673 and bringing the position to 110 shares worth $3.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2086.

Lindbrook Capital first reported a position in SUPN in Q3 2023 and has held it in 7 quarters since. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • Lindbrook Capital held 110 shares of Supernus Pharmaceuticals worth $3.6K as of Q1 2025.
  • Lindbrook Capital bought 19 Supernus Pharmaceuticals shares in Q1 2025, an estimated $673.
  • Supernus Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2086 holding.
  • Lindbrook Capital first reported a position in Supernus Pharmaceuticals in Q3 2023 and has held it in 7 quarters since.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.